The global drug repurposing market size is calculated at US$ 636.95 million in 2025, grew to US$ 730.96 million in 2026, and is projected to reach around US$ 2506.64 million by 2035. The market is expanding at a CAGR of 14.76% between 2026 and 2035.
Headquarters: Hyderabad, India
Established: 2001
Nature of Business: Provides informatics and analytics services to life sciences companies, integrating clinical, molecular, and outcomes data to accelerate drug discovery and development
Multi‑omics data analytics for early-stage R&D
Clinical data management and outcomes informatics platforms
Custom analytics services for biotechnology and pharmaceutical clients
Strong presence in India while serving global clients in the US and Europe
Supports smaller biotech firms with advanced analytics services
Enables multinational research collaborations, advancing life sciences innovation globally
Strengths:
Niche expertise in bioinformatics and cheminformatics
Strong data-driven culture and leadership
Global client servicing with cost-efficient operations
Weaknesses:
Margin pressure as a service provider
Dependence on R&D budgets which can be cyclical
Scaling high-value analytical services requires significant talent and infrastructure
Opportunities:
Growing demand for AI/ML-driven drug discovery
Expanded partnerships with pharma and biotech
Emerging markets offer new client bases
Threats:
Large pharma developing in-house analytics capabilities
Rapid technological change requiring constant upgrades
Regulatory and data privacy challenges in cross-border analytics
Acquired a US-based informatics company to strengthen global bioinformatics offerings
Reached annual revenue of ~INR 223 crore, showing healthy growth
Expanded European client share while maintaining global service delivery
Headquarters: Edinburgh, UK
Established: 2008
Nature of Business: Specialist bioinformatics company offering data analysis services for genomics, transcriptomics, and proteomics to pharma, biotech, CROs, and academia
Bioinformatics reports translating omics data into actionable insights
Data analysis services including biomarker analysis, sequencing, proteomics, and metabolomics
Support for both human and non-human research species
Serves global clients, bringing advanced bioinformatics outside traditional hubs
Located in an academic research cluster, facilitating industry-academic collaboration
Provides cost-efficient services enabling smaller firms to access cutting-edge research
Strengths:
Deep specialist expertise in bioinformatics
Platform-agnostic service flexibility
Strong global client track record
Weaknesses:
Growth tied to project availability
Competition from large CROs
Limited scalability due to specialized talent requirements
Opportunities:
Surge in genomics and multi-omics creates increased demand
Collaborations with AI/ML firms for predictive analytics
Expansion into emerging markets
Threats:
Automation and AI may commoditize parts of bioinformatics
Data security and regulatory compliance concerns
Larger firms developing in-house capabilities
Enhanced service capabilities for multiple data platforms
Active in global service markets with top pharma clients
Integrated closely with academic research clusters
Headquarters: Dallas, Texas, USA
Nature of Business: Clinical-stage oncology company using AI, machine learning, and genomics to develop precision oncology therapeutics
Vision: Reduce cost, risk, and timeline of oncology drug development using proprietary RADR® platform
LP‑300: Phase 2 trial for non-smoker NSCLC adenocarcinoma
LP‑184: Phase 1 trials in solid tumors including pancreatic, breast, bladder, CNS
LP‑284: Phase 1 in non-Hodgkin’s lymphoma
RADR® Platform: Uses AI/ML to select compounds, stratify patients, and optimize combinations
US-based, serving global oncology markets
AI-driven development supports underserved regions
Facilitates collaboration with hospitals, clinical centers, and data banks globally
Strengths:
Innovative AI/ML use in oncology
Multiple candidates in clinical development
Proprietary RADR® platform differentiates it in oncology space
Weaknesses:
Revenue dependent on clinical trial outcomes
AI/ML translation to market is unproven
High burn rate with limited product revenue
Opportunities:
Growing demand for personalized oncology therapies
Partnerships and licensing deals with larger pharma
Potential to repurpose abandoned drugs for new indications
Threats:
Clinical trial or regulatory failure risks
Competition from AI-driven drug discovery and traditional pharma
Biotech funding environment fluctuations
RADR® platform upgraded with AI-powered drug combination prediction
Funded with ~$15.9 million cash runway into June 2026
LP‑284 dosing initiated in Phase 1 trials for pancreatic and lymphoma indications
Headquarters: USA
Nature of Business: AI-driven oncology company using a tumor biobank and 3D tumor modeling to support drug discovery and personalized therapy
Value Proposition: Predicts tumor response to reduce drug development risk
AI-based tumor response prediction models
3D tumor modeling and response testing in vitro
Drug discovery support services for biopharma partners
Serves global clients with predictive oncology tools
Large tumor biobank enables diverse population modeling
Collaborates with academic institutions and smaller biotech firms
Strengths:
Proprietary tumor biobank (~150,000 samples)
Integration of AI/ML with biological modeling
Publicly listed, increasing visibility
Weaknesses:
Reliance on predictive models without market-ready drug assets
Revenue largely service-based until commercial drugs launch
Competition from other AI oncology firms
Opportunities:
Rising demand for personalized oncology tools
Licensing platform to larger pharma
Expansion into other disease areas
Threats:
Regulatory uncertainty around AI/ML in drug development
Data privacy and biobank management risks
Clients developing in-house capabilities
Developed predictive models for 21 new molecules with strong anti-tumor potential
Accuracy of 92% in predicting tumor sample responses
Expanded 3D tumor modeling services to existing client base
Headquarters: Melbourne, Australia
Established: 2014
Nature of Business: Drug repurposing company focusing on approved or under-used molecules for new indications
Lead candidate: Injectable pentosan polysulphate sodium (iPPS/PPS) for osteoarthritis
Potential applications: OA, MPS, Ross River virus, Chikungunya virus, ARDS
Strategy: Leverage known safety profiles to reduce risk and time
Targets global markets including US, EU, Canada, and Australia
Could impact millions suffering from osteoarthritis
Model encourages small biotech firms to repurpose existing molecules
Strengths:
Clinical focus on unmet needs
Repurposing reduces development risk
Publicly listed company (ASX)
Weaknesses:
No large commercial revenues yet
Success dependent on clinical trial outcomes
Limited diversification of pipeline
Opportunities:
Aging population increases OA market demand
Potential for licensing and partnerships
Apply repurposing model to other indications
Threats:
Competition from novel OA therapies
Regulatory or clinical trial failures
Funding constraints for small biotech
Focus on injectable PPS treatment for OA and other conditions
Emphasis on extracting value from under-utilized molecules
Investor communications highlight cost- and time-efficient development
Headquarters: Tokyo, Japan (R&D in Cambridge, UK)
Established: 1990
Nature of Business: Global biopharmaceutical company focused on drug discovery and early development with partnerships and licensing
StaR® platform for GPCR-targeted drug discovery
Partnered drugs: Ultibro®, Seebri®, Enerzair®
Early-stage discovery and licensing services
Japanese presence with global partnership footprint
Licensing model contributes to global therapeutic innovation
Supports treatments in neurology, immuno-oncology, gastroenterology, inflammation, and rare diseases
Strengths:
Proprietary StaR® technology platform
Global partnerships with milestone and royalty revenue
Efficient early-stage R&D operations
Weaknesses:
Revenue dependent on milestone payments and royalties
Early-stage pipeline failure risk
Operating losses due to R&D investments
Opportunities:
Expansion in GPCR-targeted therapies
Licensing and emerging market expansion
Strategic acquisitions to accelerate growth
Threats:
Competition from biotech and large pharma
Pipeline failures could affect revenue
Currency and regulatory risks
FY 2023 revenue: JPY 12,766 million (US$90.8m), operating loss reflects R&D investment
Investing in program-centric R&D and specialty commercialization
Raised US$200 million in 2020 for strategic growth
Headquarters: New Orleans, Louisiana, USA
Established: 2016
Nature of Business: Early-stage biotech focusing on drug repurposing for diseases with high unmet need such as pancreatic cancer and fibrotic diseases
Lead series: Type A – Series 2000 (fibroblast activation), Type B – Series 1000 (tumor invasion)
Platform: High-content imaging and phenotypic screening
Focus: Rapid repositioning of clinically safe molecules
US-based, aiming to impact oncology and fibrosis therapies globally
Collaborates with academic institutions and pharma partners
Offers early-stage preclinical solutions with speed and cost efficiency
Strengths:
Focused niche in drug repurposing
High-throughput screening technology
Experienced management team in oncology and fibrosis
Weaknesses:
Early-stage, dependent on partnerships and funding
Limited commercial track record
Pipeline concentrated on few indications
Opportunities:
High unmet needs in oncology and fibrosis
Potential for global licensing deals
Expand repurposing model across other disease areas
Threats:
Competition from established biotech and pharma
Regulatory approval risks
Market adoption uncertainty
Focused on pancreatic cancer and fibrosis treatment candidates
Platform enables faster identification of repurposed drugs
Active collaborations with US-based academic and clinical partners
Company Overview:
Description: A research-based biopharmaceutical company focused on developing and commercializing advanced therapies in areas of high unmet medical need. Its substantial portfolio of existing small molecules and biologics positions it strategically for drug repurposing efforts, especially in immunology and oncology.
Corporate Information:
History and Background:
Background: Formed to focus on proprietary pharmaceuticals, inheriting a rich pipeline and portfolio from Abbott Laboratories. Drug repurposing is a key strategy for life-cycle management and pipeline expansion, leveraging the known safety profiles of existing compounds.
Key Milestones/Timeline:
Business Overview:
Focus: Discovery, development, manufacture, and commercialization of innovative medicines. Drug repurposing is integrated into the R&D strategy to accelerate development timelines and reduce risk, especially in complex diseases.
Business Segments/Divisions:
Pharmaceutical products: Focused on therapeutic areas including immunology, oncology, neuroscience, and eye care.
Allergan aesthetics: Products and services related to medical aesthetics.
Geographic Presence:
Global: Operations and sales in over 70 countries worldwide.
Key markets: United States (largest market), Europe, and other international regions.
Key Offerings:
Core repurposed potential: Leveraging established drugs like Humira (adalimumab) and compounds from its pipeline for new indications.
Therapeutic focus: Immunological diseases (Crohn's disease, psoriatic arthritis), oncology, and neuroscience disorders, where repurposing can address unmet needs.
End-Use Industries Served:
Key Developments and Strategic Initiatives:
Strategic focus: Accelerating the use of artificial intelligence (AI) and data convergence to speed up drug discovery, including the identification of repurposing candidates.
R&D investment: Increased adjusted R&D investment to $10.8 billion in 2024.
Mergers & Acquisitions:
Recent focus: Acquisition of Cerevel Therapeutics and Immunogen (completed 2024) to bolster neuroscience and oncology pipelines, which also opens up new compounds for potential repurposing strategies.
Partnerships & Collaborations:
Academic/biotech collaborations: Engagements to leverage external data, genomics, and translational medicine expertise for drug discovery and repurposing insights.
Product Launches/Innovations:
Innovation focus: Advancing combination therapies in its pipeline, such as risankizumab (skyrizi) combinations for inflammatory conditions, representing a form of repositioning for existing assets.
Capacity Expansions/Investments:
2025 investment: $195 million investment in its North Chicago API manufacturing plant for expanding U.S. production capacity.
Regulatory Approvals:
2024 approvals: Continued expansion of indications for key immunology drugs (e.g., Skyrizi for ulcerative colitis, Rinvoq for pediatric patients), representing successful life-cycle management and indication expansion (a form of repurposing).
Distribution Channel Strategy:
Technological Capabilities/R&D Focus:
Core Technologies/Patents:
Research & Development Infrastructure:
Infrastructure: Global R&D centers with capabilities in high-throughput screening, translational medicine, and clinical development.
Innovation Focus Areas:
Competitive Positioning:
Position: A top-tier biopharmaceutical company globally. Strong market leader in immunology and oncology. Drug repurposing is a key tool for extending the value of its diversified portfolio.
Strengths & Differentiators:
Market Presence & Ecosystem Role:
Role: Major innovator and producer of specialized medicines. A significant end-user of drug repurposing technology for life-cycle extension and pipeline acceleration.
SWOT Analysis:
Recent News and Updates:
Press Releases:
Industry Recognitions/Awards:
General: Consistently recognized as a top global pharmaceutical company for r&d investment and innovation.
Company Overview:
Description: A focused, innovative medicines company with a powerful research-driven pipeline. Drug repurposing is a crucial part of its strategy to deliver high-value medicines faster by leveraging existing compounds across its core therapeutic areas.
Corporate Information:
History and Background:
Background: Formed from the merger of two long-standing chemical and pharmaceutical companies. Following the 2023 spin-off of Sandoz (generics/biosimilars), Novartis is now a pure-play innovative medicines company, intensifying its focus on breakthrough R&D and new technology platforms, which include advanced methods for drug repurposing.
Key Milestones/Timeline:
Business Overview:
Focus: Delivering high-value, innovative medicines to address high disease burden across four core therapeutic areas. Drug repurposing is supported by a large small-molecule and biologics library and is a cost-effective way to accelerate treatments.
Business Segments/Divisions:
Innovative medicines: This is the sole focus post-Sandoz spin-off, covering its branded pharmaceuticals.
Geographic Presence:
Key Offerings:
End-Use Industries Served:
Key Developments and Strategic Initiatives:
Mergers & Acquisitions:
Recent focus: Value-creating, bolt-on acquisitions and early-stage deals to strengthen the pipeline, including in radioligand therapy (RLT) and AI capabilities relevant to discovery and repurposing.
Partnerships & Collaborations:
Academic/industry alliances: Network of over 300 academic and 100 industry alliances for mutual scientific interest, including repurposing collaborations (e.g., AI-driven drug discovery partnerships).
Product Launches/Innovations:
Innovation focus: Advancing its pipeline of over 30 potential high-value new medicines. Emphasis on life-cycle management for key brands through indication expansion (repurposing).
Capacity Expansions/Investments:
R&D investment: Ongoing significant investment in R&D, including advanced platforms (XRNA, RLT) and enhanced technical capabilities (e.g., si/XRNA manufacturing).
Capital allocation: Balanced approach with investments in organic business, including R&D and capes.
Regulatory Approvals:
2024 approvals: Reached key innovation milestones, including Scemblix FDA accelerated approval for 1L Ph+ CML-CP and Kisqali EC approval for hr+/her2- stage II and III EBC (expanded indications).
Distribution Channel Strategy:
Technological Capabilities/R&D Focus:
Core Technologies/Patents:
Research & Development Infrastructure:
Infrastructure: Global biomedical research centers. Streamlined development portfolio with increased focus and enhanced competencies post-Sandoz spin-off.
Innovation Focus Areas:
Competitive Positioning:
Position: Among the top global innovative medicines companies. Strong financial base and a focused strategy on breakthrough science. Its deep expertise across multiple therapeutic areas and technology platforms gives it a strong advantage in drug repositioning.
Strengths & Differentiators:
Market Presence & Ecosystem Role:
Role: Global leader in innovative pharmaceuticals. Active in shaping the future of medicine through investment in new modalities and efficient drug discovery/repurposing models.
SWOT Analysis:
Recent News and Updates:
Press Releases:
2024: Multiple media releases detailing strong financial results, positive clinical trial data, and regulatory approvals across its core therapeutic areas.
Industry Recognitions/Awards:
Key Companies and Their contributions and offerings
This leverages the identification of candidate drugs (through computational or experimental methods), evaluation of their potential in preclinical models, the conduct of clinical trials, and finally, post-market monitoring.
Key Players: BenevolentAI, Recursion Pharmaceuticals, and Healx, etc.
This includes testing of existing drugs for new uses, often fast-tracking them by studying their known safety profiles, and ultimately getting approved by various regulatory bodies.
Key Players: Brigham and Women's Hospital, Karolinska Institutet, etc.
The market provides innovative treatments to patients with rapid and more cost-effective results by determining new uses for existing drugs.
Source- Bristol Myers Squibb (BMS), Cipla, Dr Reddy, etc.
Partner with our experts to explore the Drugs Repurposing Market at sales@towardshealthcare.com
